Featured Research

from universities, journals, and other organizations

Potential new target for ovarian cancer identified

Date:
August 16, 2010
Source:
University of Texas M. D. Anderson Cancer Center
Summary:
For the first time, Salt Inducible Kinase 2 (SIK2) has been found to play a critical role in cell division and to regulate the response of some ovarian cancers to chemotherapy.

For the first time, Salt Inducible Kinase 2 (SIK2) has been found to play a critical role in cell division and to regulate the response of some ovarian cancers to chemotherapy.

Findings were reported by researchers from The University of Texas MD Anderson Cancer Center in the August issue of Cancer Cell. The study adds to growing evidence that combination therapies targeting different phases of the cell division cycle are vital for optimal cancer treatment.

Researchers found that depleting SIK2 from ovarian cancers sensitized the cancer cells to paclitaxel, a commonly prescribed chemotherapeutic agent that inhibits cell division, making the drug more effective in stopping the cancer's growth. Levels of the SIK2 protein are increased in approximately 30 percent of ovarian cancers and are associated with poorer survival in women with the disease.

"There is a large window of opportunity to improve the effectiveness of existing chemotherapies by modifying the sensitivity of cancer cells to the drugs," said study senior author Robert C. Bast, Jr., M.D., vice president for translational research at MD Anderson. "In our search for proteins that are responsible for that sensitivity, we found that SIK2 was required for cell division and that its inhibition offers a novel approach to improving chemotherapy for ovarian cancer that deserves further study."

Although mitosis-inhibiting drugs are used successfully to treat a range of cancers, only about 50 percent of ovarian cancer patients respond to taxanes and it is not yet possible to identify in advance which patients will benefit. As a result, many patients receive taxanes arbitrarily as part of a combination of chemotherapy drugs.

SIK2 role in regulating cell division previously unknown

Bast and first author Ahmed Ashour Ahmed, M.D., Ph.D., a former postdoctoral fellow in Bast's lab who is now a member of the faculty at Oxford University, analyzed nearly 780 pools of siRNAs to identify proteins that alter sensitivity to paclitaxel. SIK2, a previously described member of the "AMPK" family of kinases that are active in resting cells, was found to regulate sensitivity to paclitaxel and to prevent division after doubling of DNA during proliferation of cancer cells. SIK2 was found in the cell centrosomes, which must split in order to direct distribution of chromosomes into each daughter cell.

"The discovery that SIK2 plays a role in cell cycle regulation is groundbreaking since to date it has been linked to cellular metabolism and energy balance," Ahmed said. "In addition to improving the response of some cancer to taxane, our findings add support to emerging evidence that cancer cell metabolism and mitosis functions are coupled."

According to researchers, drugs that inhibit SIK2 are needed to permit future clinical studies. Such drugs do not yet exist but knowing the right target is an important first step.

The study was funded by grants from the Ovarian Cancer Research Fund, the National Foundation for Cancer Research, the Zarrow Foundation and the M.D. Anderson Ovarian Cancer Specialized Program in Research Excellence funded by the National Cancer Institute.

Co-authors are Zhen Lu, M.D., Xiao-Feng Le, M.D., Ph.D., Pablo Vivas-Mejia, Ph.D., Gabriel Lopez-Berestein, M.D., Geoffrey Grandjean, Geoffrey Bartholomeusz, Ph.D., and Warren Liao, Ph.D., Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center; Nicholas B. Jennings and Anil K. Sood, M.D., Department of Gynecologic Oncology, MD Anderson Cancer Center; Dariush Etemadmoghadam, Ph.D., and David Bowtell, Ph.D., Cancer Genomics and Genetics Laboratory, Peter MacCallum Cancer Centre; Luisa Capalbo and David M. Glover, Ph.D., Department of Genetics, University of Cambridge; Rodrigo O. Jacamo, Ph.D., and Michael Andreeff, M.D., Ph.D., Department of Stem Cell Transplantation and Cellular Therapy, MD Anderson Cancer Center; Nuno Barbosa-Morais, Ph.D., Computational Biology Group, Department of Oncology, University of Cambridge; and the Australian Ovarian Cancer Study Group.


Story Source:

The above story is based on materials provided by University of Texas M. D. Anderson Cancer Center. Note: Materials may be edited for content and length.


Journal Reference:

  1. Ahmed Ashour Ahmed, Zhen Lu, Nicholas B. Jennings, Dariush Etemadmoghadam, Luisa Capalbo, Rodrigo O. Jacamo, Nuno Barbosa-Morais, Xiao-Feng Le, Pablo Vivas-Mejia, Gabriel Lopez-Berestein, Geoffrey Grandjean, Geoffrey Bartholomeusz, Warren Liao, Michael Andreeff, David Bowtell, David M. Glover, Anil K. Sood, Robert C. Bast. SIK2 Is a Centrosome Kinase Required for Bipolar Mitotic Spindle Formation that Provides a Potential Target for Therapy in Ovarian Cancer. Cancer Cell, 2010; DOI: 10.1016/j.ccr.2010.06.018

Cite This Page:

University of Texas M. D. Anderson Cancer Center. "Potential new target for ovarian cancer identified." ScienceDaily. ScienceDaily, 16 August 2010. <www.sciencedaily.com/releases/2010/08/100816122138.htm>.
University of Texas M. D. Anderson Cancer Center. (2010, August 16). Potential new target for ovarian cancer identified. ScienceDaily. Retrieved July 24, 2014 from www.sciencedaily.com/releases/2010/08/100816122138.htm
University of Texas M. D. Anderson Cancer Center. "Potential new target for ovarian cancer identified." ScienceDaily. www.sciencedaily.com/releases/2010/08/100816122138.htm (accessed July 24, 2014).

Share This




More Health & Medicine News

Thursday, July 24, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

New Painkiller Designed To Discourage Abuse: Will It Work?

New Painkiller Designed To Discourage Abuse: Will It Work?

Newsy (July 24, 2014) The FDA approved Targiniq ER on Wednesday, a painkiller designed to keep users from abusing it. Like any new medication, however, it has doubters. Video provided by Newsy
Powered by NewsLook.com
Doctor At Forefront Of Fighting Ebola Outbreak Gets Ebola

Doctor At Forefront Of Fighting Ebola Outbreak Gets Ebola

Newsy (July 24, 2014) Sheik Umar Khan has treated many of the people infected in the Ebola outbreak, and now he's become one of them. Video provided by Newsy
Powered by NewsLook.com
Condemned Man's US Execution Takes Nearly Two Hours

Condemned Man's US Execution Takes Nearly Two Hours

AFP (July 24, 2014) America's death penalty debate raged Thursday after it took nearly two hours for Arizona to execute a prisoner who lost a Supreme Court battle challenging the experimental lethal drug cocktail. Duration: 00:55 Video provided by AFP
Powered by NewsLook.com
China's Ageing Millions Look Forward to Bleak Future

China's Ageing Millions Look Forward to Bleak Future

AFP (July 24, 2014) China's elderly population is expanding so quickly that children struggle to look after them, pushing them to do something unexpected in Chinese society- move their parents into a nursing home. Duration: 02:07 Video provided by AFP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

    Health News

      Environment News

        Technology News



          Save/Print:
          Share:

          Free Subscriptions


          Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

          Get Social & Mobile


          Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

          Have Feedback?


          Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
          Mobile: iPhone Android Web
          Follow: Facebook Twitter Google+
          Subscribe: RSS Feeds Email Newsletters
          Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins